z-logo
Premium
NFKB 1 − 94ins/del ATTG polymorphism is a novel prognostic marker in first line‐treated multiple myeloma
Author(s) -
Varga Gergely,
Mikala Gábor,
Andrikovics Hajnalka,
Koszarska Magdalena,
Balassa Katalin,
Ádám Emma,
Kozma András,
Tordai Attila,
Masszi Tamás
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13197
Subject(s) - bortezomib , hazard ratio , medicine , multiple myeloma , allele , genotype , oncology , gastroenterology , confidence interval , biology , gene , genetics
Summary Nuclear factor kappa B ( NFKB ) plays an important role in multiple myeloma ( MM ), and bortezomib affects this pathway. We retrospectively analysed the effect of the NFKB 1 − 94ins/del ATTG polymorphism on the survival of 295 MM patients treated at a single centre. The median progression‐free survival ( PFS ) was 790 (659–921) d in patients with NFKB 1 homozygous insertion genotype (I/I, n  = 99) and 624 (515–733) d in deletion‐carriers (I/D&D/D, n  = 196, P  = 0·013). In multivariate analysis, I/I carriers showed a favourable PFS compared to I/D&D/D with a hazard ratio of 0·622 (0·457–0·847), P  = 0·003, in addition to international staging system ( ISS ) score, fluorescence in situ hybridization ( FISH ) risk score, age and bortezomib treatment. I/I patients benefited more from bortezomib treatment [ PFS 902 (703–1101) and 580 (343–817), P  = 0·008] than I/D&D/D patients [ PFS 659 (487–831) and 488 (323–653), P  = 0·531]; in addition the beneficial effect of low ISS score was not observed in the I/D&D/D group [ PFS 639 (454–824) and 650 (458–842), P  = 0·226], while it was clear in I/I patients [ PFS 1140 (803–1477) and 580 (408–752), P  < 0·001]. We conclude that homozygous carriers of the insertion allele of the NFKB 1 − 94ins/del ATTG polymorphism have a better prognosis and probably benefit more from bortezomib treatment than MM patients carrying the deletion allele.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here